Press releases
- Insulet to Announce First Quarter 2024 Financial Results on May 9, 2024
- Insulet Appoints Ana Maria Chadwick as Chief Financial Officer
- Insulet’s Randomized Controlled Trial (OP5-003) Demonstrates Omnipod® 5 Automated Insulin Delivery System is Superior to Pump Therapy
- Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
- Insulet Reports Full Year 2023 Revenue Increase of 30% (30% Constant Currency¹) and Fourth Quarter 2023 Revenue Increase of 38% Year-Over-Year (37% Constant Currency)
- Insulet to Present at The Raymond James & Associates 45th Annual Institutional Investors Conference
- Insulet Announces CE Mark Approval of Omnipod® 5 Integration with Abbott FreeStyle Libre 2 Plus Sensor
- Imperative Care Announces Four Senior Leadership Appointments
More ▼
Key statistics
As of last trade, Insulet Corp (GOV:BER) traded at 151.90, 26.22% above the 52 week low of 120.35 set on Oct 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 151.90 |
---|---|
High | 151.90 |
Low | 151.90 |
Bid | 155.50 |
Offer | 156.00 |
Previous close | 154.70 |
Average volume | 6.33 |
---|---|
Shares outstanding | 70.02m |
Free float | 69.80m |
P/E (TTM) | 58.26 |
Market cap | 11.50bn USD |
EPS (TTM) | 2.82 USD |
Data delayed at least 15 minutes, as of Apr 26 2024 07:08 BST.
More ▼